anti-FGFR1 mAb program (AVEO Pharmaceuticals)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-FGFR1 mAb program (AVEO Pharmaceuticals)
Drug Alias Nameanti-fibroblast growth factor receptor-1 monoclonal antibody program (AVEO Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionFibroblast growth factor receptor 1 antagonists
TargetsFibroblast growth factor receptor 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAVEO Oncology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAVEO Oncology
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A